PLAA Suppresses Ovarian Cancer Metastasis Via METTL3-mediated M6a Modification of TRPC3 Mrna

Zhangjin Shen,Lingkai Gu,Yuwan Liu,Lingfang Wang,Jiawei Zhu,Sangsang Tang,Xinyi Wei,Jiaying Wang,Songfa Zhang,Xinyu Wang,Xiaodong Cheng,Xing Xie,Weiguo Lu
DOI: https://doi.org/10.1038/s41388-022-02411-w
IF: 8.756
2022-01-01
Oncogene
Abstract:Wide metastasis contributes to a high death rate in ovarian cancer, and understanding of the molecular mechanism helps to find effective targets for metastatic ovarian cancer therapy. It has been found that phospholipase A2-activating protein (PLAA) is inactivated in some cancers, but its role in cancer metastasis remains unknown. Here, we found that PLAA was significantly downregulated in ovarian cancer highly metastatic cell lines and patients, and the low expression of PLAA was associated with poorer prognosis and high-risk clinicopathological features of patients. PLAA inhibited the migration and invasion of ovarian cancer cells and metastasis of transplanted tumor in the orthotopic xenograft mouse model. Meanwhile, PLAA inhibited metastasis of ovarian cancer by inhibiting transient receptor potential channel canonical 3 (TRPC3)-mediated the intracellular Ca 2+ level. Mechanistically, PLAA inhibited methyltransferase-like 3 (METTL3) expression through the ubiquitin-mediated degradation, and METTL3 stabilized TRPC3 mRNA expression via N6-methyladenosine (m 6 A) modification. Our study verified the function and mechanism of the PLAA-METTL3-TRPC3 axis involved in ovarian cancer metastasis, with a view to providing a potential therapeutic approach for ovarian cancer.
What problem does this paper attempt to address?